The share price of Conatus Pharmaceuticals Inc. [NASDAQ: CNAT] inclined by $0.36, presently trading at $0.43. The company’s shares saw 70.12% gains compared to the lowest price in the period of the last 52 weeks, set at $0.25 recorded on 09/10/19. The last few days have been benevolent to the share price as CNAT jumped by +26.56% during the last week, even though the stock is still down by -4.97% compared to 0.09 of all time high it touched on 09/11/19. However, the stock had a poor performance during the past 3 months, roughly gaining 18.72%, while additionally dropping -92.49% during the last 12 months. Conatus Pharmaceuticals Inc. is said to have a 12-month price target set at $1.60. That means that the stock has a strong potential to acquire 1.17% increase from the current trading price.

Conatus Pharmaceuticals Inc. [NASDAQ:CNAT]: Analyst Rating and Earnings

Its stock price has been found in the range of 0.25 to 6.74. This is compared to its latest closing price of $0.36.

Pay attention to the next-scheduled financial results for this company to be released, which is slated for Thu 7 Nov (In 57 Days).

Fundamental Analysis of Conatus Pharmaceuticals Inc. [CNAT]

Now let’s turn to look at profitability: with a current Operating Margin for Conatus Pharmaceuticals Inc. [CNAT] sitting at -54.42, this company’s Net Margin is now -42.30%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is -53.32, and its Return on Invested Capital has reached -66.70%. Its Return on Equity is -65.02, and its Return on Assets is -27.55. These metrics suggest that this Conatus Pharmaceuticals Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

What about valuation? This company’s Enterprise Value to EBITDA is 1.63. The Enterprise Value to Sales for this firm is now -0.90. Conatus Pharmaceuticals Inc. [CNAT] has a Price to Book Ratio of 2.09.

Shifting the focus to workforce efficiency, Conatus Pharmaceuticals Inc. [CNAT] earns $1,083,419 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 9.54 and its Total Asset Turnover is 0.51. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.56 and its Current Ratio is 2.56. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Conatus Pharmaceuticals Inc. [CNAT] has 33.23M shares outstanding, amounting to a total market cap of $11.93M. Its stock price has been found in the range of 0.25 to 6.74. At its current price, it has moved down by -93.69% from its 52-week high, and it has moved up 70.12% from its 52-week low.

This stock’s Beta value is currently 2.19, which indicates that it is 7.60% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 74.77. This RSI suggests that Conatus Pharmaceuticals Inc. is currently Overbought.

Conclusion: Is Conatus Pharmaceuticals Inc. [CNAT] a Reliable Buy?

Shares of Conatus Pharmaceuticals Inc. [CNAT], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.